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Introduction
The rising prevalence of type 2 diabetes will impose anincreasing burden of diabetic complications on healthcaresystems worldwide. The results of the UK Prospective
Diabetes Study (UKPDS), and other studies, confirm the potential
of effective glycaemic control to improve and extend the lives of
people with type 2 diabetes. However, current management
algorithms do not achieve sufficient glycaemic control in most
patients to realise these improved clinical outcomes. We need a
greater readiness to employ intensification of antidiabetic thera-
py earlier and in a manner that supports good compliance if we
aim to maintain effective, long-term control of type 2 diabetes.  
Audit of current diabetes management 
Current management guidelines for type 2 diabetes in Europe
and the USA set out challenging targets for glycaemic control.1-3
However, most type 2 diabetic patients managed in the commu-
nity are not meeting these goals, and a survey of 6,544 patients
in the UK (figure 1) suggests that during the 1990s only one in
seven patients achieved HbA1C < 7.0%.4 Further evidence from
Germany shows that in 1998 only 26% of patients achieved
HbA1C < 6.5%.5 Data from the Third National Health and
Nutrition Examination Survey (NHANES III) in the USA comple-
ment the European experience.6 The majority of patients with
diabetes severe enough to receive pharmacological treatment
had HbA1C above the US goal level of < 7%, and a substantial
minority (20–30%) had HbA1C > 9% (figure 2).
We will face even greater challenges from type 2 diabetes in
the future.  The increasing obesity of the US population has dri-
ven a marked rise in the prevalence of type 2 diabetes.  It is well
known that obesity, particularly visceral adiposity, is associated
with the development of insulin resistance and glucose intoler-
ance.7,8 Between 1990 and 1998, the average weight of men
and women in the USA increased by 3.4 kg and 3.9 kg, respec-
tively.9 During the same period, the prevalence of diabetes in the
USA increased from 4.9% to 6.5%.  The number of states with
a prevalence of type 2 diabetes below 4% declined from seven-
teen to four, and the number of states with more than 6% of cit-
izens with type 2 diabetes increased from two to twenty-five (fig-
ure 3).9
The global prevalence of type 2 diabetes is increasing and it
is estimated that the number of people with diabetes will rise
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Figure 1. Patients achieving pre-defined treatment goals in a 
metropolitan area of the UK4
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Figure 2. Mean HbA1C in cohorts of patients on different antidiabetic 
therapies in the USA (1988–1994): data from NHANES III6
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from 150 million in the year 2000 to 220 million in 2010.10
Furthermore, half of all cases of type 2 diabetes are believed to
be undiagnosed, and the insidious damage due to long-term
hyperglycaemia is often evident even when patients present for
diagnosis. Ultimately, some 60% of type 2 diabetic patients will
die a cardiovascular death, with only one patient in five achiev-
ing a normal life span. The earlier diabetes is diagnosed, the
more there is to lose: patients diagnosed in middle age (40–49
years) lose an estimated 7–10 years of life, compared with 5–7
years for patients diagnosed at age 50–59 years and 3–5 years
for patients diagnosed at age 60–69 years.11 This does not bode
well for individuals diagnosed with type 2 diabetes at 20–30
years of age, who represent the fastest-growing segment of the
type 2 diabetic population.
The cost of treating type 2 diabetes is high, especially man-
aging the complications which reduce both the quality and dura-
tion of life.12,13 More evidence from the CODE-2 study showed
that, while diabetic patients without complications were 30%
more expensive to manage compared with patients with other
conditions, overall management costs for patients with both
macrovascular and microvascular complications were more than
four-fold greater than those for non-diabetic patients.5
Worldwide, the cost of managing diabetes alone accounts for as
much as 2–3% of total healthcare expenditure in every country.14
The global pandemic of type 2 diabetes will represent the single
greatest challenge to healthcare systems worldwide during the
early decades of this century.
Importance of effective glycaemic control
The results of the UKPDS, among other studies, leave us in no
doubt that effective control of glycaemia improves and extends
the lives of patients with type 2 diabetes.  The main analysis of
the UKPDS determined the effects of intensive management on
glycaemia and clinical outcomes. This was based on treatment
with insulin or a sulphonylurea compared with a conventional
management policy of diet and exercise in 3,867 patients fol-
lowed for an average of ten years.15
An epidemiological analysis of the UKPDS revealed that a
reduction in HbA1C of 1% was associated with reductions in the
risk of a range of diabetic complications (figure 4), including dia-
betes-related death (-21%), myocardial infarction (-14%),
microvascular disease (-37%) and peripheral vascular disease
(-43%).16 
The association between HbA1C and risk of complications
was continuous and extended downwards into the normal range
(HbA1C < 6.0%).  Thus, each 1% reduction in HbA1C would be
expected to deliver improvements in clinical outcomes.
Part of the UKPDS evaluated the effect of metformin, in com-
parison with diet-based treatment and intensive glycaemic
ACHIEVING BEST PRACTICE
VOLUME 2 ISSUE 4  . JULY/AUGUST 2002 291
Figure 3. Obesity and type 2 diabetes in the USA: a) mean body weight in American men and women; b) changing prevalences of type 2 diabetes9 
1990
Year
60
M
ea
n
 w
ei
g
h
t 
(k
g
)
1994 1998
70
80
90 Men Women
Year
1990
0
N
u
m
b
er
 o
f 
st
at
es
1994 1998
17
7
2
28
36
22
4
6
25
10
20
30
40
Prevalence of type 2 diabetes
< 4% < 4–6% > 6%
Figure 4. Reduction in risk in diabetic complications associated with 
each 1% reduction in HbA1C in the UKPDS16
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management with a sulphonylurea or insulin, in 1,704 over-
weight patients (defined as being > 120% of ideal body
weight).17 Metformin significantly reduced the risk of any dia-
betes-related complication (by 32%), diabetes-related death (by
42%) and fatal or non-fatal myocardial infarction (by 39%),
while trends towards reduced risk of stroke, peripheral vascular
disease or microvascular complications did not achieve statistical
significance. 
The results of the UKPDS provide a strong base of evidence
to underpin the benefits of effective glycaemic control.
Identifying and overcoming the barriers to improving our man-
agement of type 2 diabetes will allow us to realise the benefits
seen within the UKPDS for all of our type 2 diabetic patients. 
Overcoming the barriers to effective control of
diabetes
The dual metabolic defect of type 2 diabetes
Type 2 diabetes in almost all cases is driven by a dual metabolic
defect of insulin resistance and a relative impairment of insulin
secretion. Insulin resistance is usually well established by the time
that diabetes is diagnosed, and remains at a relatively constant
level throughout the remainder of the course of the disease.18,19
Although the impairment of beta-cell function also begins a
number of years before the patient presents for diagnosis,20
patients may still have sufficient beta-cell capacity to increase
insulin secretion in an attempt to compensate for the insulin
resistance for some years.  As a result, a period of hyperinsuli-
naemia is often observed during the early years of clinical type 2
diabetes.  Eventually, however, beta-cell function declines to the
point where glycaemic control degenerates rapidly and treat-
ment with exogenous insulin will be required.  
Antidiabetic treatments may induce a short-term improve-
ment in beta-cell function,20 and some success has been achieved
in delaying or preventing the onset of type 2 diabetes in glucose-
intolerant individuals using lifestyle modification or metformin
treatment.21 On the other hand, no treatment has yet been
demonstrated to slow the decline in beta-cell function durably in
patients with established type 2 diabetes.  Thus, type 2 diabetes
can be considered to represent a ‘moving target’,22 in that the
underlying pathophysiology is dynamic in nature and unlikely to
respond adequately to any single therapy during long-term treat-
ment.
Limitations of diet/exercise and oral antidiabetic
monotherapy
Current management algorithms for type 2 diabetes call for ini-
tial treatment with lifestyle modification followed by oral antidi-
abetic monotherapy. Therapy with diet and exercise controlled
HbA1C in only about one quarter of patients in the UKPDS after
three years of treatment, and in less than 10% of patients after
nine years of treatment (figure 5).23 Data from the UKPDS have
confirmed the limited efficacy of monotherapy in controlling gly-
caemia in the type 2 diabetic patient over the long term.  Clearly,
the majority of these patients would benefit from intensification
of therapy using oral antidiabetic agents.  
Even then, the dual metabolic defect underlying type 2 dia-
betes complicates the design of antidiabetic pharmacotherapy.
Current oral antidiabetic monotherapy can address only one of
the endocrine defects underlying the disease as its primary mech-
anism of action.  Attempts to improve efficacy by increasing the
dose of monotherapy may increase the likelihood of side effects24
that often cause patients to discontinue treatment.  For example,
insulin secretagogues (sulphonylureas or meglitinides) are associ-
ated with hypoglycaemia or weight gain in some patients.  The
principal side effect of metformin is diarrhoea, though this can
be minimised by careful titration of therapy.  Metformin has also
been associated with lactic acidosis, although the risk of this seri-
ous side effect is very low (three cases per 100,000 patient-years
of treatment).25 Thiazolidinediones cause weight gain, along
with oedema in some patients, and have a limited indication in
Europe.  Finally, α-glucosidase inhibitors induce frequent and
troublesome gastrointestinal side effects and the need for fre-
quent daily dosing may hinder compliance (see below).
For these reasons, long-term antidiabetic monotherapy will
be sufficiently effective for only a minority of patients.  For exam-
ple, in the UKPDS, therapy with a sulphonylurea, metformin or
insulin controlled HbA1C to below 7% in less than half of the
patient population after three years of treatment, and in only
about one quarter of patients or less after nine years of treat-
ment (figure 5).23 These data emphasise the need to challenge
the way that we manage type 2 diabetes, starting from the early
stages of the disease, in order to maintain protection from dia-
betic complications from the point of diagnosis.   
Moving away from failure-based glycaemic         
management
The progressive nature of type 2 diabetes requires regular adjust-
ment of therapy to retain metabolic control.  All too often, how-
ever, management strategies for type 2 diabetes are ‘failure-
based’, in that there is a tendency to persist with monotherapy
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Figure 5. Patients in the UKPDS achieving HbA1C < 7.0% on different
treatment regimens23
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until glycaemic control has been lost, perhaps irretrievably.  The
maximum efficacy of an oral antidiabetic treatment is achieved
within 2–3 months,26,27 so that intensification of therapy will be
required if glycaemic control is not achieved.  Furthermore,
increasing the dose of an insulinotropic agent beyond half of the
maximally recommended dosage usually produces little addition-
al efficacy.27-29
An early switch to antidiabetic combination treatment that
addresses the dual endocrine defects of insulin resistance and
beta-cell dysfunction, would deliver a markedly greater reduction
in HbA1C for such patients and would provide a prompt and clin-
ically important reduction in the risk of diabetic complications, as
described above.16 Furthermore, there is evidence that physicians
may tolerate higher levels of hyperglycaemia in patients who
receive more complex antidiabetic regimens, compared with
those receiving diet and exercise or oral antidiabetic monothera-
py.  A survey of primary care physicians in the USA found that,
on average, diet and exercise therapy would commence when
fasting plasma glucose (FPG) reached 7.4 mmol/L (134 mg/dL)
(figure 6).  The same survey showed that patients would not
receive an oral antidiabetic combination, or oral therapy plus
insulin, until further marked deteriorations in glycaemia had
been observed (figure 6). These data imply that patients requir-
ing more intensive therapy are being exposed unnecessarily to
hyperglycaemia.  
A new approach to diabetes management is needed which
recognises the urgent need to control glycaemia as a central part
of the therapeutic strategy.  This requires a greater readiness on
the part of physicians to intensify antidiabetic therapy earlier and
more frequently, using rational combinations of antidiabetic
treatments with complementary mechanisms of action. For
example, the combination of metformin, which addresses insulin
resistance as its primary mechanism, with an insulinotropic agent
such as a sulphonylurea or meglitinide, which enhance beta-cell
function, addresses both components of the dual endocrine
defects of type 2 diabetes.  
Well-designed clinical studies support the use of such combi-
nations to deliver better glycaemic control than oral monothera-
py in patients previously treated with diet27,30 or oral antidiabetic
monotherapy.31-35 Figure 7 shows improved efficacy with met-
formin and glibenclamide (glyburide in the USA), as a single
tablet (Glucovance®), compared with either agent given as
monotherapy in patients previously treated with diet, metformin
or a sulphonylurea. The incidence of hypoglycaemic symptoms
with the lower dosage strength of the single combination tablet
(which could be used to initiate combination therapy) was either
lower than30 or similar to glibenclamide alone.34,35 While there is
clinical evidence supporting the use of metformin and a sulpho-
nylurea in combination, combinations of other oral antidiabetic
agents may also be of benefit.  
The use of such single-tablet combinations differs from the
conventional use of free combinations.  With a free combination,
the first component is usually titrated to the maximum efficacy,
tolerability or permitted dose. The second component is then
added at a low dose and the titration process repeated.  With a
single-tablet combination, treatment can commence with both
components at a relatively low dose and then titrated in parallel.
This approach uses potential synergy between the components
to enhance glucose-lowering efficacy with relatively low doses of
both components.  
Poor compliance with therapy
Type 2 diabetic patients bear a burden of polypharmacy36 which
is a barrier to compliance.37,38 Indeed, many patients need to take
as many as ten different medications every day for their diabetes
and concurrent conditions. Given the need to take different
medications, with different dosage frequencies and different
numbers of tablets at different times of the day, it is hardly sur-
prising that many patients are unable to follow treatment regi-
mens closely.  The Diabetes Audit and Research in Tayside,
Scotland (DARTS) study provides a quantitative evaluation of the
impact of regimen complexity on compliance with antidiabetic
therapy.39,40 The medication details of 2,920 patients were
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Figure 6. Levels of glycaemia at which US physicians stated their 
intention to apply intensified antidiabetic therapies  
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followed retrospectively for 12 months, and information on pre-
scriptions issued were used in the calculation of an ‘Adherence
Index’, an estimate of the extent of actual therapeutic coverage
from the antidiabetic treatment.  Patients with an Adherence
Index > 90% were considered to have complied adequately with
therapy. 
Only about 30% of patients met this goal while receiving
monotherapy with either a sulphonylurea or metformin but
adherence to therapy worsened by 13% when a free  combina-
tion of these agents was used (figure 8). Furthermore, annual
drug coverage was greater (p<0.01) in patients receiving
monotherapy with a sulphonylurea (300 days) or metformin (302
days) than in patients receiving a free combination of these
antidiabetic agents (266 days).  
The DARTS study confirms the adverse impact of complex
treatment regimens on routine adherence to therapy.  Even the
most effective treatment cannot benefit patients if it is not taken
as prescribed.  It is important that intensification of treatment
regimens do not reduce patient compliance.  The use of novel
formulations, including single-tablet combinations, provides an
avenue for further evaluation.
Looking ahead
The challenging glycaemic targets in current management guide-
lines provide a useful framework for improving patient outcomes
in type 2 diabetes.  We know that intensive oral antidiabetic reg-
imens are effective, and reduce the risk of diabetic complica-
tions15,17 without impairing patients’ quality of life.41 A greater
readiness to treat to target and to intensify therapy earlier will
form a key element in future diabetes management strategies.
Single-tablet combinations offer the potential to maximise antidi-
abetic efficacy without reducing patient compliance and single-
tablet combinations are already accepted in other fields of med-
icine.42,43
Current treatment algorithms need updating to include the
use of single-tablet combinations in the management of type 2
diabetes.  Indeed, a recent review of target-driven care conclud-
ed that the development of single-tablet combination therapies
‘seems of the utmost priority for the prevention of complications
of type 2 diabetes’.44
References
1. European Diabetes Policy Group. A desktop guide to type 2 diabetes
mellitus. Diabet Med 1999;16:716-30.
2. American Diabetes Association: clinical practice recommendations.
Diabetes Care 1999;22(suppl 1):S1-114.
3. American Association of Clinical Endocrinologists.  Medical guidelines for
the management of diabetes mellitus: The AACE system of intensive dia-
betes self-management – 2002 Update. Endocrine Practice 2002;8(suppl
1):40-82.
4. New JP, Hollis S, Campbell F et al. Measuring clinical performance and
outcomes from diabetes information systems: an observational study.
Diabetologia 2000;43:836-43.
5. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A.  Costs
of type 2 diabetes in Germany. Results of the CODE-2 study. Dtsch Med
Wochenschr 2001;126:585-9. 
6. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS.  Racial and
ethnic differences in glycemic control of adults with type 2 diabetes.
Diabetes Care 1999;22:403-08.
7. Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG.
Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensi-
tive and insulin-resistant black men with NIDDM.  Int J Obes Relat Metab
Disord 1995;19:846-50. 
8. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE.  Body composi-
tion, visceral fat, leptin, and insulin resistance in Asian Indian men.  J Clin
Endocrinol Metab 1999;84:137-44.
9. Mokdad AS, Ford EH, Bowman BA et al. Diabetes trends in the US:
1990–1998. Diabetes Care 2000;23:1278–83.
10. Day C. The rising tide of type 2 diabetes. Br J Diabetes Vasc Dis
2001;1:37-43.
11. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) dia-
betes mellitus. Diabetologia 1987;30:123-31.
12. Gray A, Raikou M, McGuire A et al. Cost effectiveness of an intensive
blood glucose control policy in patients with type 2 diabetes: economic
analysis alongside randomised controlled trial (UKPDS 41). BMJ 2000;
320:1373-8.
13. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting
from type 2 diabetes in the US. Diabetes Care 2002;25:476-81.
14. Jönsson B.  The economic impact of diabetes. Diabetes Care 1998;21
(suppl 3):C7-10.
15. UK Prospective Diabetes Study Group. Intensive blood glucose control
with sulphonylurea or insulin compared with conventional treatment and
risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet
1998;352:837-53.
ACHIEVING BEST PRACTICE
Key messages
 Effective glycaemic control improves and extends the
lives of people with type 2 diabetes
 Poor glycaemic control remains widespread in
community practice
 We need to overcome barriers to effective glycaemic
control
 Earlier use of combination therapy, in a manner that
supports patient compliance, is required
Figure 8. Impact of polypharmacy on adherence to an antidiabetic 
regimen in the DARTS study39
Sulphonylurea
0
A
d
h
er
en
ce
 (
%
)
p<0.05
10
20
30
40
Metformin Sulphonylurea
+ metformin
(free
combination)
}
THE BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE294
 at LMU Muenchen on May 16, 2013dvd.sagepub.comDownloaded from 
16. Stratton MI, Adler AI, Neil AW et al. Association of glycaemia with
macrovascular and microvascular complications of type 2 diabetes
(UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood
glucose control with metformin on complications in overweight patients
with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65. 
18. DeFronzo RA, Bonnadonna RC, Ferrannini E.  Pathogenesis of NIDDM.  A
balanced overview. Diabetes Care 1992;15:318-68.
19. DeFronzo RA.  Insulin resistance: a multifaceted syndrome responsible for
NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J
Med 1997;50:191-7.
20. UK Prospective Diabetes Study Group.  UK prospective diabetes study 16.
Overview of 6 years' therapy of type II diabetes: a progressive disease. UK
Prospective Diabetes Study Group. Diabetes 1995;44:1249-58.
21. Diabetes Prevention Program Research Group. Reduction in the inci-
dence of type 2 diabetes with lifestyle intervention or metformin.  N Engl
J Med 2002;346:393-403.
22. Bailey CJ. Diabetes control: Treating a moving target. Internal Med 1996;
17:90-101.
23. Turner RC, Cull CA, Frighi V, Holman RR. Glycaemic control with diet, sul-
fonylurea, metformin or insulin in patients with type 2 diabetes mellitus:
Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;
281:2005-12.
24. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral
antidiabetic agents. Drug Saf 1994;11:223-41.
25. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2
diabetes mellitus. Drug Saf 1999;20:489-503.
26. Haupt E, Knick B, Koschinsky T et al.  Oral antidiabetic combination ther-
apy with sulphonylureas and metformin. Diabete Metab 1991;27:224-
31.
27. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy,
response prediction and dose-response relations of treatment with met-
formin and sulphonylurea, alone and in primary combination. Diabet
Med 1994;11:953-60.
28. Gribble FM, Manley SE, Levy JC.  Randomized dose ranging study of the
reduction of fasting and postprandial glucose in type 2 diabetes by
nateglinide (A-4166).  Diabetes Care 2001;24:1221-25.
29. Goldberg RB, Holvey SM, Schneider J. A dose-response study of
glimepiride in patients with NIDDM who have previously received sul-
fonylurea agents.  The Glimepiride Protocol #201 Study Group.  Diabetes
Care 1996;19:849-56.
30. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D.  Simultaneous gly-
buride/metformin monotherapy is superior to component monotherapy
as initial pharmacological treatment for type 2 diabetes. Diab Obes
Metab 2002;4:201-08.
31. Moses R, Carter J, Slobodniuk R et al.  Effect of repaglinide addition to
metformin monotherapy on glycemic control in patients with type 2 dia-
betes.  Diabetes Care 1999;22:119-24.
32. DeFronzo RA, Goodman AM.  Efficacy of metformin in patients with
non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:541-9.
33. Charpentier G, Fleury F, Kabir M et al. Improved glycaemic control by
addition of glimepiride to metformin monotherapy in type 2 diabetic
patients.  Diabet Med 2001;16:828-34.
34. Marre M, Howlett H, Lehert P, Allavoine T.  Improved glycaemic control
with metformin-glibenclamide combined tablet therapy (Glucovance®) in
type 2 diabetic patients inadequately controlled on metformin. Diabet
Med 2002;19:673-80.
35. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D.  Glyburide/
metformin combination product is safe and efficacious in patients with
type 2 diabetes failing sulfonylurea therapy.  Diabetes Obes Metab (in
press).
36. Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM. The development of
polypharmacy. A longitudinal study. Fam Pract 2000;17:261-7. 
37. Paes AHP, Bakker A, Soe-Agnie S-J. Impact of dosage frequency on
patient compliance. Diabetes Care 1997;20:1512-17.
38. Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-year follow-up of antidi-
abetic drug use, nonadherence, and mortality in a defined population
with type 2 diabetes mellitus. Clin Ther 1999;21:1045-57.
39. Morris AD, Brennan GM, Macdonald TM, Donnan PT. Population-Based
Adherence to Prescribed Medication in Type 2 Diabetes: A Cause for
Concern. Diabetes 2000;49(suppl 1):A76.
40. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral
hypoglycaemic medication in a population of patients with type 2 dia-
betes: a retrospective cohort study.  Diabet Med 2002;19:279-84.
41. UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2
diabetic patients is affected by complications but not by policies to
improve blood glucose or blood pressure control. Diabetes Care 1999;
22:1125-36.
42. Guidelines Subcommittee. 1999 World Health Organisation –
International Society of Hypertension. Guidelines for the Management of
Hypertension. J Hypertens 1999;17:151-83.
43. Joint National Committee. Sixth National Report of the Joint National
Committee on Prevention, Detection, Evaluation and Treatment of High
Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-46.
44. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ
2002;324:1577-80.
VOLUME 2 ISSUE 4  . JULY/AUGUST 2002 295
ACHIEVING BEST PRACTICE
 at LMU Muenchen on May 16, 2013dvd.sagepub.comDownloaded from 
